VolitionRx Limited (NYSE American: VNRX) announced the release of a new clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. The study, conducted with researchers and clinicians at France’s Hospices Civils de Lyon, found that levels of the assay’s H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival. A prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. The paper is currently under peer review.
The findings support the potential use of Nu.Q Cancer to help personalize treatment selection and improve clinical decision-making, according to Volition. The company also noted that clinical certification of the test at Hospices Civils de Lyon has been completed and that it is preparing a reimbursement submission in France under the RIHN framework. Volition is pursuing commercialization opportunities with hospital networks and potential licensing partners internationally, with reimbursement representing a key milestone toward routine clinical use in France.
For business and technology leaders, this development underscores the growing role of epigenetics in precision medicine. The ability to stratify lung cancer patients by mortality risk could enable more tailored therapies, potentially improving outcomes and reducing healthcare costs. The assay, which uses a simple blood test, could also facilitate earlier monitoring of disease progression. As Volition moves toward reimbursement in France and seeks international partners, the technology may soon become a standard tool in oncology, impacting treatment protocols and patient management globally.
Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company’s website at https://volition.com/.
The full press release is available at https://ibn.fm/dhJZ6.
